Efficacy and Safety of Chiauranib in Relapsed/Refractory Ovarian Cancer: a Single-arm, Open-label, Multi-site, Exploratory Study
Phase of Trial: Phase I/II
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Chiauranib (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Chipscreen Biosciences
- 31 Aug 2018 Biomarkers information updated
- 18 Dec 2017 Status changed from not yet recruiting to recruiting.
- 21 Nov 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.